Metabolic and Muscle Profile in ICU Survivors

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorAnne-Françoise Rousseau

About this trial

More and more patients survive a critical illness requiring admission to the intensive care unit, but they may be left with sequelae that are independent of the initial pathology. From a physical standpoint, the most visible complication is intensive care unit-acquired muscle weakness. A major factor in the development and persistence of muscle dysfunction appears to be the inflammatory response and the neuroendocrine stress response triggered by the initial critical insult. Persistence of inflammation beyond ICU discharge has been demonstrated in several studies. In response to inflammation, there is also increased oxidative stress associated with mitochondrial dysfunction.

The objectives of the present study are therefore:

to determine whether the broad inflammatory and metabolic profile of patients who have survived an ICU stay can predict the trajectory of muscle performance over the three months following ICU discharge; to compare this profile and muscle performance with those of non-critically ill surgical patients who have undergone a standardized inflammatory stress of lower intensity than that associated with critical illness; to investigate mitochondrial function in skeletal striated muscle after ICU stay, in light of the inflammatory and metabolic profile; to assess whether abnormalities in mitochondrial function also affect tissues other than skeletal muscle, in particular circulating blood mononuclear cells.

Eligibility criteria

Qualifiers

anticipated ICU stay >= 7 days

Major abdominal surgery

elective surgery

Disqualifiers

Active malignancy

Inherited metabolic disorder

Known muscle disease

Pregnancy

Trial design

Treatments tested in this trial

  • Inflammation markers
  • Blood nucleosomes
  • Erythrocyte membrane fatty acid content
  • measurement of myokines
  • Resting energy expendure
  • body composition
  • Omics
  • Monocyte profile

Treatment groups

100 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Anne-Françoise Rousseau

Lead sponsor

University of Liege

Sponsor institution